| 朱银兴.养阴益气汤联合化疗治疗中晚期非小细胞肺癌近期疗效观察及对T细胞亚群、VEGF和IL-6表达影响[J].浙江中西医结合杂志,2021,31(9): |
| 养阴益气汤联合化疗治疗中晚期非小细胞肺癌近期疗效观察及对T细胞亚群、VEGF和IL-6表达影响 |
| Clinical observation of Yangyin Yiqi Decoction combined with chemotherapy in the treatment of advanced non-small cell lung cancer and its influence on T cell subsets, VEGF and IL-6 expression |
| 投稿时间：2020-12-15 修订日期：2021-08-08 |
| DOI： |
| 中文关键词: 养阴益气汤 化疗 中晚期 非小细胞肺癌 近期疗效 T细胞亚群 血管内皮生长因子 白介素-6 |
| 英文关键词:Yangyin Yiqi Decoction chemotherapy advanced stage non-small cell lung cancer short-term efficacy T cell subsets vascular endothelial growth factor interleukin-6 |
| 基金项目: |
|
| 摘要点击次数: 389 |
| 全文下载次数: 2 |
| 中文摘要: |
| 目的：探讨养阴益气汤联合化疗治疗中晚期非小细胞肺癌(NSCLC)患者近期疗效及对T细胞亚群、血管内皮生长因子(VEGF)和白介素-6(IL-6)表达影响。方法：选择2018年1月~2020年6月我院中晚期NSCLC患者94例,按照随机抽签法分为实验组(n=47)与对照组(n=47)。实验组采用养阴益气汤联合化疗治疗,对照组采用化疗治疗。2组均以21d为1疗程,均于3个疗程评价。比较2组近期疗效和生存质量；化疗前与化疗后T细胞亚群、VEGF和IL-6水平变化；及不良反应情况。结果：实验组近期总有效率(68.08%)高于对照组(46.80%)(P<0.05)。实验组生存质量提高率(72.34%)高于对照组(51.06%)(P<0.05)。对照组患者治疗后CD3+、CD4+和CD4+/CD8+较治疗前降低(P<0.05)；实验组患者治疗后CD3+、CD4+和CD4+/CD8+较治疗前升高(P<0.05)；实验组患者治疗后CD3+、CD4+和CD4+/CD8+高于对照组(P<0.05)。2组患者化疗后血清VEGF和IL-6水平较化疗前降低(P<0.05)；实验组患者治疗后血清VEGF和IL-6水平低于对照组(P<0.05)。实验组胃肠道反应、乏力、肝功能异常、白细胞减少和血小板减少发生率低于对照组(P<0.05)。结论：养阴益气汤联合化疗治疗中晚期NSCLC患者近期疗效良好,且可改善患者免疫功能,降低VEGF和IL-6表达,及可减轻不良反应。 |
| 英文摘要: |
| Objective: To investigate the short-term efficacy of Yangyin Yiqi Decoction combined with chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC) and its influence on the expression of T cell subsets, vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6). Methods: The 94 patients with advanced NSCLC in our hospital from January 2018 to June 2020 divided experimental group (n=47) and control group (n=47). The experimental group was treated with Yangyin Yiqi Decoction combined with chemotherapy, while the control group was treated with chemotherapy. Two groups were treated with 21 days as a course of treatment, and were evaluated in three courses. The short-term efficacy and quality of life, changes of T cell subsets, VEGF and IL-6 levels before and after chemotherapy, and adverse reactions were compared between the two groups. Results: the experimental group effective rate (68.08%) was higher control group (46.80%) (P<0.05). The improvement rate of quality of life (72.34%) was higher control group (51.06%) (P<0.05). After treatment, the control group CD3+, CD4+ and CD4+/CD8+ were lower before treatment (P<0.05); the experimental group CD3+, CD4+ and CD4+/CD8+ were higher before treatment (P<0.05); after treatment, the experimental group CD3+, CD4+ and CD4+/CD8+ were higher control group (P<0.05). After treatment, the two groups serum VEGF and IL-6 was lower before treatment (P<0.05); after treatment, the experimental group serum VEGF and IL-6 was lower control group (P<0.05). The experimental group incidence of gastrointestinal reaction, fatigue, abnormal liver function, leucopenia and thrombocytopenia were lower control group (P<0.05). Conclusion: Yangyin Yiqi Decoction Combined with chemotherapy has a good short-term effect in the treatment of advanced NSCLC, and can improve the immune function of patients, reduce the expression of VEGF and IL-6, and reduce the adverse reactions. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
